Growth Hormone Therapy: The Complete Guide for 2026

What Is Growth Hormone Therapy?

The growth hormone axis operates through a tightly regulated feedback loop. The hypothalamus releases growth hormone-releasing hormone (GHRH), which stimulates somatotroph cells in the anterior pituitary to secrete GH. Simultaneously, somatostatin (SRIF) inhibits GH release. Ghrelin, produced primarily in the stomach, provides a third input through growth hormone secretagogue receptors (GHSR). Once released, GH travels to the liver and other tissues, stimulating production of insulin-like growth factor 1 (IGF-1), which mediates most of GH’s anabolic and regenerative effects.

GH release is pulsatile, with the largest pulse occurring during slow-wave (deep) sleep. Exercise, fasting, hypoglycemia, and certain amino acids also trigger GH secretion. Age-related decline occurs through reduced GHRH signaling, increased somatostatin tone, decreased ghrelin sensitivity, and impaired pituitary reserve. This decline correlates with increased visceral fat, decreased lean mass, reduced bone density, thinning skin, impaired immune function, and cognitive changes.

Treatment approaches fall into two categories: direct replacement with recombinant HGH (somatropin) and indirect stimulation using secretagogue peptides. Direct HGH provides precise dose control but bypasses the feedback loop, potentially causing more side effects. Secretagogues work within the natural axis, producing more physiological pulsatile release with fewer side effects but less predictable outcomes. Long-acting GH analogs like somapacitan now offer once-weekly dosing with sustained steady-state levels.

Growth Hormone Compound Library

Direct GH Replacement

GHRH Analogs

Growth Hormone Releasing Peptides (GHRPs)

IGF-1 & GH Fragments

Common Protocols

Recombinant HGH for anti-aging and body composition is typically dosed at 1–3 IU per day (0.3–1.0 mg) via subcutaneous injection, administered in the evening or morning on an empty stomach. Starting low (1 IU daily) and titrating up based on IGF-1 levels and side effects is standard practice. Clinical GH deficiency protocols use 0.2–0.4 mg daily, adjusted every 1–2 months based on IGF-1 response. Somapacitan is dosed at 1.5–8 mg once weekly.

Secretagogue stacks are preferred by many clinicians for their physiological approach. CJC-1295 (without DAC) at 100 mcg combined with Ipamorelin at 100–200 mcg is injected subcutaneously before bed, five nights per week. Sermorelin at 200–500 mcg nightly is a well-established alternative. GHRP-2 or GHRP-6 at 100–300 mcg can be dosed 2–3 times daily for stronger GH pulses, but must be taken on an empty stomach (fasted for 2+ hours) as insulin and glucose blunt the response.

MK-677 at 10–25 mg orally before bed provides 24-hour GH elevation with notable deep sleep enhancement. It does not desensitize and can be used continuously, but requires monitoring of fasting glucose and insulin due to ghrelin-mediated insulin resistance. Tesamorelin at 2 mg daily subcutaneously is the only FDA-approved GHRH analog for visceral fat reduction.

IGF-1 LR3 at 20–80 mcg daily (divided into pre- and post-workout doses) is used in 4–6 week cycles. HGH Fragment 176-191 at 250–500 mcg twice daily (morning fasted and pre-bed) targets fat loss specifically. All GH-axis protocols cycle 12 weeks on and 4–8 weeks off to prevent receptor desensitization (except MK-677 and prescribed HGH, which may be used continuously under medical supervision).

Who Should Consider GH Therapy?

Adults with diagnosed GH deficiency (confirmed by stimulation testing such as the insulin tolerance test or glucagon stimulation test) have a clear medical indication for replacement. Symptoms include increased visceral adiposity, decreased lean mass, reduced exercise capacity, impaired bone density, elevated cardiovascular risk markers, poor sleep quality, and diminished quality of life.

Beyond clinical deficiency, adults over 35 experiencing age-related GH decline may explore secretagogue peptides for body composition optimization, sleep improvement, skin quality, and recovery enhancement. Individuals with HIV-associated lipodystrophy have FDA-approved indications for tesamorelin. GH therapy is contraindicated in active malignancy, uncontrolled diabetes, active proliferative retinopathy, and during acute critical illness. Anyone with a history of cancer should discuss GH axis stimulation with their oncologist given the theoretical concern of IGF-1-driven tumor growth.

Monitoring & Safety

The primary biomarker for GH therapy is serum IGF-1, checked at baseline, 6 weeks, and 12 weeks, then every 3–6 months. Target IGF-1 is the upper quartile of the age-adjusted reference range. Levels chronically above the reference range increase risk of side effects and theoretical cancer concerns. Fasting glucose, fasting insulin, HbA1c, and HOMA-IR should be checked at baseline and quarterly, as GH therapy can reduce insulin sensitivity.

A comprehensive metabolic panel, CBC, lipid panel, and thyroid function (free T3, free T4, TSH) complete the monitoring panel. GH therapy can increase T4-to-T3 conversion, potentially unmasking subclinical hypothyroidism. Cortisol levels may also shift, as GH inhibits 11-beta-hydroxysteroid dehydrogenase type 1. Patients on thyroid or cortisol replacement may need dose adjustments.

Common side effects of GH therapy are dose-dependent: water retention, joint stiffness, carpal tunnel-like symptoms, and morning hand numbness. These typically resolve with dose reduction. Serious adverse effects are rare at physiological doses but include intracranial hypertension (extremely rare), worsening of pre-existing scoliosis in children, and theoretical acceleration of occult malignancies. Regular physical exams, age-appropriate cancer screening, and vigilant symptom monitoring are essential.

Frequently Asked Questions

What is the difference between HGH and secretagogue peptides?

HGH (somatropin) is the actual growth hormone protein injected directly. Secretagogues (CJC-1295, Ipamorelin, Sermorelin, GHRPs) are signaling peptides that tell your pituitary to release your own GH. The advantage of secretagogues is more physiological pulsatile release with built-in feedback regulation, meaning you are less likely to achieve supraphysiological levels. The advantage of direct HGH is precise dosing and predictable IGF-1 response. Many clinicians now prefer secretagogues for anti-aging and reserve direct HGH for documented deficiency.

Does GH therapy cause cancer?

This is a common concern, but current evidence does not support a causal link at physiological replacement doses. Large-scale studies including the SAGhE and HypoCCS databases have not shown increased cancer incidence in adults on GH replacement. However, IGF-1 is a growth factor, and chronically elevated levels could theoretically promote existing but undetected tumors. This is why keeping IGF-1 within the reference range and maintaining routine cancer screening is emphasized.

Can I use GH peptides without a prescription?

Recombinant HGH is a controlled substance in the US (Schedule III in some states) and requires a prescription. Secretagogue peptides like CJC-1295, Ipamorelin, and Sermorelin are available through compounding pharmacies with a prescription. MK-677 (Ibutamoren) occupies a gray area—it is not FDA-approved but is available as a research chemical. For safety, all GH-axis therapies should be used under medical supervision with proper bloodwork monitoring.

How does sleep affect growth hormone?

Approximately 70% of daily GH secretion occurs during slow-wave (deep) sleep, primarily in the first half of the night. Sleep deprivation, poor sleep quality, late-night eating (elevated insulin), alcohol, and blue light exposure all suppress nocturnal GH release. Optimizing sleep hygiene—consistent bedtime, cool dark room, avoiding food 2–3 hours before bed—is the single most effective non-pharmacological intervention for GH output. This is also why most peptide protocols recommend bedtime dosing.